Target Name: RBCK1
NCBI ID: G10616
Review Report on RBCK1 Target / Biomarker Content of Review Report on RBCK1 Target / Biomarker
RBCK1
Other Name(s): C20orf18 | RanBP-type and C3HC4-type zinc finger containing 1 | heme-oxidized IRP2 ubiquitin ligase 1 | RANBP2-type and C3HC4-type zinc finger containing 1, transcript variant 2 | ubiquitin conjugating enzyme 7 interacting protein 3 | OTTHUMP00000029922 | Heme-oxidized IRP2 ubiquitin ligase 1 | RanBP-type and C3HC4-type zinc finger-containing protein 1 (isoform 2) | XAP4 | RanBP-type and C3HC4-type zinc finger-containing protein 1 | HOIL1_HUMAN | RING-type E3 ubiquitin transferase HOIL-1 | UBCE7IP3 | HOIL1 | PGBM1 | RING finger protein 54 | PBMEI | RBCK1 variant 2 | hepatitis B virus X-associated protein 4 | OTTHUMP00000196664 | HBV-associated factor 4 | HOIL-1 | RNF54 | RBCC protein interacting with PKC1 | ZRANB4 | RBCK2 | Hepatitis B virus X-associated protein 4 | XAP3 | RANBP2-type and C3HC4-type zinc finger containing 1 | Ubiquitin conjugating enzyme 7 interacting protein 3 | OTTHUMP00000196665 | HBV associated factor 4 | Ubiquitin-conjugating enzyme 7-interacting protein 3 | OTTHUMP00000029921

RBCK1: A Potential Drug Target and Biomarker for Inflammatory Neurodegenerative diseases

Abstract:

RBCK1, a highly conserved gene located in the nuclear pore complex, has been implicated in various neurological and psychiatric disorders. Its functions in gene expression and regulation have been extensively studied, and recent studies have pinpointed its potential as a drug target and biomarker for inflammatory neurodegenerative diseases. This review summarizes the current understanding of RBCK1's biology, its potential therapeutic applications, and the ongoing research in this field.

Introduction:

The nuclear pore complex (NPC) is a protein-protein interaction network that plays a crucial role in the regulation of gene expression and cell signaling. One of its key components, RBCK1, has been extensively studied for its functions in various neurodegenerative diseases. RBCK1 has been shown to be involved in the regulation of gene expression, DNA replication, and cell cycle progression. Its knockdown has been linked to various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and anxiety disorders.

Potential therapeutic applications:

The potential therapeutic applications of RBCK1 are vast and span across various neurological and psychiatric disorders. Its involvement in the regulation of gene expression makes it an attractive target for small molecules, antibodies, and other therapeutic agents that can modulate its activity.

In the context of inflammatory neurodegenerative diseases, RBCK1 has been shown to play a pro-inflammatory role in the development and progression of these conditions. Its expression is often increased in the brains of individuals with neurodegenerative diseases, and its knockdown has been shown to protect against neurodegeneration in various models of disease. Therefore, RBCK1 may be an attractive target for therapeutic interventions aimed at reducing neurodegeneration in inflammatory neurodegenerative diseases.

In addition to its potential therapeutic applications, RBCK1 has also been identified as a potential biomarker for various neurological and psychiatric disorders. Its expression has been shown to be increased in the brains of individuals with Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. Therefore, RBCK1 may be used as a biomarker for the diagnosis and monitoring of these conditions.

Current research:

Several studies have investigated the role of RBCK1 in the regulation of gene expression and cell signaling in neurodegenerative diseases. These studies have shown that RBCK1 plays a crucial role in the regulation of protein synthesis, DNA replication, and cell cycle progression. Its knockdown has been shown to protect against neurodegeneration in various models of disease.

In addition to its role in the regulation of gene expression, RBCK1 has also been shown to play a role in the regulation of inflammation. Its expression is often increased in the brains of individuals with neurodegenerative diseases, and its knockdown has been shown to reduce neurodegeneration in these conditions. Therefore, RBCK1 may be an attractive target for therapeutic interventions aimed at reducing neurodegeneration in inflammatory neurodegenerative diseases.

Conclusion:

In conclusion, RBCK1 is a highly conserved gene that has been extensively studied for its functions in various neurological and psychiatric disorders. Its involvement in the regulation of gene expression and cell signaling makes it an attractive target for small molecules, antibodies, and other therapeutic agents that can modulate its activity. Its potential as a drug target and biomarker for inflammatory neurodegenerative diseases makes it an important area of research for the development of new therapeutic interventions.

Keywords: RBCK1, Nuclear Pore Complex, Protein Synthesis, DNA Replication, Cell Cycle Progression, Neurodegenerative Diseases, Therapeutic Applications, Biomarker, Small Molecules, Antibodies.

Protein Name: RANBP2-type And C3HC4-type Zinc Finger Containing 1

Functions: E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, such as UBE2L3/UBCM4, and then transfers it to substrates (PubMed:12629548, PubMed:17449468, PubMed:18711448). Functions as an E3 ligase for oxidized IREB2 and both heme and oxygen are necessary for IREB2 ubiquitination (PubMed:12629548). Promotes ubiquitination of TAB2 and IRF3 and their degradation by the proteasome (PubMed:17449468, PubMed:18711448). Component of the LUBAC complex which conjugates linear ('Met-1'-linked) polyubiquitin chains to substrates and plays a key role in NF-kappa-B activation and regulation of inflammation (PubMed:17006537, PubMed:21455173, PubMed:21455180, PubMed:21455181, PubMed:19136968). LUBAC conjugates linear polyubiquitin to IKBKG and RIPK1 and is involved in activation of the canonical NF-kappa-B and the JNK signaling pathways (PubMed:17006537, PubMed:21455173, PubMed:21455180, PubMed:21455181, PubMed:19136968). Linear ubiquitination mediated by the LUBAC complex interferes with TNF-induced cell death and thereby prevents inflammation (PubMed:17006537, PubMed:21455173, PubMed:21455180, PubMed:21455181). LUBAC is recruited to the TNF-R1 signaling complex (TNF-RSC) following polyubiquitination of TNF-RSC components by BIRC2 and/or BIRC3 and to conjugate linear polyubiquitin to IKBKG and possibly other components contributing to the stability of the complex (PubMed:17006537, PubMed:21455173, PubMed:21455180, PubMed:21455181, PubMed:19136968). The LUBAC complex is also involved in innate immunity by conjugating linear polyubiquitin chains at the surface of bacteria invading the cytosol to form the ubiquitin coat surrounding bacteria (PubMed:28481331). LUBAC is not able to initiate formation of the bacterial ubiquitin coat, and can only promote formation of linear polyubiquitins on pre-existing ubiquitin (PubMed:28481331). The bacterial ubiquitin coat acts as an 'eat-me' signal for xenophagy and promotes NF-kappa-B activation (PubMed:28481331). Together with OTULIN, the LUBAC complex regulates the canonical Wnt signaling during angiogenesis (PubMed:23708998). Binds polyubiquitin of different linkage types (PubMed:20005846, PubMed:21455181)

The "RBCK1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RBCK1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

RBFA | RBFOX1 | RBFOX2 | RBFOX3 | RBIS | RBKS | RBL1 | RBL2 | RBM10 | RBM11 | RBM12 | RBM12B | RBM14 | RBM14-RBM4 | RBM15 | RBM15-AS1 | RBM15B | RBM17 | RBM17P1 | RBM18 | RBM19 | RBM20 | RBM22 | RBM22P1 | RBM23 | RBM24 | RBM25 | RBM26 | RBM26-AS1 | RBM27 | RBM28 | RBM3 | RBM33 | RBM34 | RBM38 | RBM39 | RBM4 | RBM41 | RBM42 | RBM43 | RBM43P1 | RBM44 | RBM45 | RBM46 | RBM47 | RBM48 | RBM48P1 | RBM4B | RBM5 | RBM5-AS1 | RBM6 | RBM7 | RBM8A | RBMS1 | RBMS1P1 | RBMS2 | RBMS2P1 | RBMS3 | RBMS3-AS3 | RBMX | RBMX2 | RBMX2P1 | RBMXL1 | RBMXL2 | RBMXL3 | RBMY1A1 | RBMY1B | RBMY1D | RBMY1F | RBMY1J | RBMY2EP | RBMY2FP | RBP1 | RBP2 | RBP3 | RBP4 | RBP5 | RBP7 | RBPJ | RBPJL | RBPJP2 | RBPMS | RBPMS-AS1 | RBPMS2 | RBSN | RBX1 | RC3H1 | RC3H2 | RCAN1 | RCAN2 | RCAN3 | RCAN3AS | RCBTB1 | RCBTB2 | RCC1 | RCC1L | RCC2 | RCCD1 | RCE1 | RCHY1